Mirabella Financial Services LLP Buys Shares of 4,131 argenx SE (NASDAQ:ARGX)

Mirabella Financial Services LLP bought a new position in shares of argenx SE (NASDAQ:ARGX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 4,131 shares of the company’s stock, valued at approximately $2,539,000.

Other institutional investors also recently modified their holdings of the company. GeoWealth Management LLC boosted its stake in argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after acquiring an additional 18 shares during the last quarter. Whipplewood Advisors LLC bought a new position in shares of argenx during the fourth quarter worth $37,000. Global Retirement Partners LLC grew its holdings in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after buying an additional 48 shares during the period. FIL Ltd bought a new stake in shares of argenx in the 4th quarter valued at $38,000. Finally, Jones Financial Companies Lllp raised its stake in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after buying an additional 61 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARGX has been the subject of several recent analyst reports. Wells Fargo & Company increased their price target on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Piper Sandler upped their price target on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. Oppenheimer raised their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, Robert W. Baird upped their target price on shares of argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $699.28.

argenx Trading Up 1.5 %

NASDAQ ARGX opened at $596.20 on Friday. argenx SE has a 12 month low of $352.77 and a 12 month high of $678.21. The stock has a 50 day moving average of $602.53 and a 200-day moving average of $605.93. The company has a market cap of $36.23 billion, a PE ratio of -677.50 and a beta of 0.60.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, sell-side analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.